EXAS Exact Sciences Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: EXAS

Price (delayed)

$63.24

Market cap

$11.48B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.13

Enterprise value

$13.43B

Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer. Exact Sciences Corp. launched Cologuard in 2014, the first ...

Highlights
Exact Sciences's EPS has soared by 68% YoY and by 29% from the previous quarter
The company's net income has surged by 67% YoY and by 28% QoQ
The company's debt rose by 4.4% YoY
The company's quick ratio fell by 2.6% QoQ
Sector: Healthcare
Industry: Diagnostics & Research
Website: https://www.exactsciences.com/
Peers: MYGN VCYT

Key stats

What are the main financial stats of EXAS
Market
Shares outstanding
181.53M
Market cap
$11.48B
Enterprise value
$13.43B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.64
Price to sales (P/S)
4.56
EV/EBIT
N/A
EV/EBITDA
257.27
EV/Sales
5.37
Earnings
Revenue
$2.5B
EBIT
-$182.3M
EBITDA
$52.2M
Free cash flow
$31.93M
Per share
EPS
-$1.13
Free cash flow per share
$0.18
Book value per share
$17.39
Revenue per share
$13.88
TBVPS
$12.29
Balance sheet
Total assets
$6.47B
Total liabilities
$3.33B
Debt
$2.55B
Equity
$3.15B
Working capital
$679.67M
Liquidity
Debt to equity
0.81
Current ratio
2.32
Quick ratio
1.91
Net debt/EBITDA
37.34
Margins
EBITDA margin
2.1%
Gross margin
73.8%
Net margin
-8.2%
Operating margin
-8.6%
Efficiency
Return on assets
-3.2%
Return on equity
-6.6%
Return on invested capital
-5%
Return on capital employed
-3.1%
Return on sales
-7.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EXAS stock price

How has the Exact Sciences stock price performed over time
Intraday
-0.46%
1 week
0.03%
1 month
1.84%
1 year
-4.49%
YTD
-14.52%
QTD
-8.43%

Financial performance

How have Exact Sciences's revenue and profit performed over time
Revenue
$2.5B
Gross profit
$1.85B
Operating income
-$215.01M
Net income
-$204.15M
Gross margin
73.8%
Net margin
-8.2%
The company's net margin has surged by 73% YoY and by 30% QoQ
The operating margin has surged by 70% year-on-year and by 23% since the previous quarter
The company's net income has surged by 67% YoY and by 28% QoQ
The operating income has surged by 64% year-on-year and by 19% since the previous quarter

Growth

What is Exact Sciences's growth rate over time

Valuation

What is Exact Sciences stock price valuation
P/E
N/A
P/B
3.64
P/S
4.56
EV/EBIT
N/A
EV/EBITDA
257.27
EV/Sales
5.37
Exact Sciences's EPS has soared by 68% YoY and by 29% from the previous quarter
The stock's price to book (P/B) is 39% less than its 5-year quarterly average of 6.0 and 17% less than its last 4 quarters average of 4.4
The company's equity rose by 3.4% YoY
EXAS's price to sales (P/S) is 53% less than its 5-year quarterly average of 9.7 and 21% less than its last 4 quarters average of 5.8
EXAS's revenue is up by 20% year-on-year and by 3.9% since the previous quarter

Efficiency

How efficient is Exact Sciences business performance
Exact Sciences's ROS has soared by 75% YoY and by 34% from the previous quarter
The company's return on invested capital has surged by 69% YoY and by 31% QoQ
The ROE has soared by 67% YoY and by 28% from the previous quarter
EXAS's return on assets has surged by 67% year-on-year and by 29% since the previous quarter

Dividends

What is EXAS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EXAS.

Financial health

How did Exact Sciences financials performed over time
The total assets is 95% more than the total liabilities
The total assets has grown by 3.9% YoY
EXAS's current ratio is down by 3.7% QoQ and by 2.5% YoY
The company's debt is 19% lower than its equity
The company's debt rose by 4.4% YoY
The company's equity rose by 3.4% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.